UFT for head and neck cancers: its tissue concentrations and effects on lymphocyte subpopulations.
UFT, a combination of the masked compound of 5-fluorouracil (FT-207) and uracil, was given to head and neck cancer patients for 1 week preoperatively and for 8 weeks postoperatively. Drug concentrations were examined in the surgically removed tissues. The concentrations of FT-207, 5-fluorouracil, and uracil were higher in tumor tissues than in normal tissues. The lymphocyte subpopulations were assessed by cytofluorometry with monoclonal antibodies. There was no evidence that adjuvant chemotherapy with UFT specifically suppresses immunocompetent cells. We therefore conclude that further clinical evaluation of adjuvant chemotherapy with UFT would be worthwhile.
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007121:Immunocompetence / Q000187:drug effects*; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects*; D008875:Middle Aged; D005641:Tegafur / Q000494:pharmacology; D014018:Tissue Distribution; D014498:Uracil / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D005641:Tegafur; D014498:Uracil